Cerecor Raises $22 Million Series A Financing
(firmenpresse) - BALTIMORE, MD -- (Marketwire) -- 04/04/12 -- , a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, announced today that it has raised over US$22 million in an overallotment of its January 2012 Series A preferred stock financing. The offering, which was placed with accredited investors including members of Cerecor's , significantly exceeded the offering maximum of US$15 million. Maxim Group, LLC of New York, NY acted as placement agent in connection with the offering.
"The completion of this financing is an important step in bringing our lead product, for the treatment of chronic and acute cough, to the market and to support our early preclinical efforts in . We are delighted by the enthusiastic response to our offering, as it confirms the quality of our Company, its and our ," stated Blake M. Paterson, M.D., Co-founder & CEO of Cerecor.
About Cerecor Inc.
Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization.
For More Information, contact:
John Dierkes
Kennedy Advisors
(410) 935-9334
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2012 - 11:30 Uhr
Sprache: Deutsch
News-ID 1100217
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BALTIMORE, MD
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 182 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cerecor Raises $22 Million Series A Financing
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cerecor Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
